182 related articles for article (PubMed ID: 9076457)
1. Long-term follow-up of cytostatic intravesical instillation in patients with superficial bladder carcinoma. Is short-term, intensive instillation better than maintenance therapy?
Schwaibold H; Pichlmeier U; Klingenberger HJ; Huland H
Eur Urol; 1997; 31(2):153-9. PubMed ID: 9076457
[TBL] [Abstract][Full Text] [Related]
2. [Comparison of the effectiveness between long-term instillation of mitomycin C and short-term prophylaxis with MMC or bacille Calmette-Guérin. Study of patients with non-muscle-invasive urothelial cancer of the urinary bladder].
Isbarn H; Budäus L; Pichlmeier U; Conrad S; Huland H; Friedrich MG
Urologe A; 2008 May; 47(5):608-15. PubMed ID: 18317718
[TBL] [Abstract][Full Text] [Related]
3. Cytostatic intravesical instillation in patients with superficial bladder carcinoma for the prevention of recurrent tumors.
Huland H; Klöppel G; Otto U; Feddersen I; Brachmann W; Hubmann H; Kaufmann J; Knipper W; Lantzius-Beninga F
Eur Urol; 1988; 14(3):202-6. PubMed ID: 3133216
[TBL] [Abstract][Full Text] [Related]
4. Combined local bladder hyperthermia and intravesical chemotherapy for the treatment of high-grade superficial bladder cancer.
Gofrit ON; Shapiro A; Pode D; Sidi A; Nativ O; Leib Z; Witjes JA; van der Heijden AG; Naspro R; Colombo R
Urology; 2004 Mar; 63(3):466-71. PubMed ID: 15028439
[TBL] [Abstract][Full Text] [Related]
5. The effect of repeat transurethral resection on recurrence and progression rates in patients with T1 tumors of the bladder who received intravesical mitomycin: a prospective, randomized clinical trial.
Divrik RT; Yildirim U; Zorlu F; Ozen H
J Urol; 2006 May; 175(5):1641-4. PubMed ID: 16600720
[TBL] [Abstract][Full Text] [Related]
6. Long-term efficacy of maintenance bacillus Calmette-Guérin versus maintenance mitomycin C instillation therapy in frequently recurrent TaT1 tumours without carcinoma in situ: a subgroup analysis of the prospective, randomised FinnBladder I study with a 20-year follow-up.
Järvinen R; Kaasinen E; Sankila A; Rintala E;
Eur Urol; 2009 Aug; 56(2):260-5. PubMed ID: 19395154
[TBL] [Abstract][Full Text] [Related]
7. Long-term mitomycin C instillation after transurethral resection of superficial bladder carcinoma: influence on recurrence, progression and survival.
Huland H; Otto U; Droese M; Klöppel G
J Urol; 1984 Jul; 132(1):27-9. PubMed ID: 6427483
[TBL] [Abstract][Full Text] [Related]
8. Long-term versus short-term doxorubicin hydrochloride instillation after transurethral resection of superficial bladder cancer.
Flamm J
Eur Urol; 1990; 17(2):119-24. PubMed ID: 2178939
[TBL] [Abstract][Full Text] [Related]
9. 17-year follow-up of a randomized prospective controlled trial of adjuvant intravesical doxorubicin in the treatment of superficial bladder cancer.
Cheng CW; Chan PS; Chan LW; Chan CK; Ng CF; Lai MM
Int Braz J Urol; 2005; 31(3):204-11. PubMed ID: 15992422
[TBL] [Abstract][Full Text] [Related]
10. Results of a prospective randomized study assessing the efficacy of fluorescent cystoscopy-assisted transurethral resection and single instillation of doxorubicin in patients with non-muscle-invasive bladder cancer.
Rolevich AI; Zhegalik AG; Mokhort AA; Minich AA; Vasilevich VY; Polyakov SL; Krasny SA; Sukonko OG
World J Urol; 2017 May; 35(5):745-752. PubMed ID: 27604374
[TBL] [Abstract][Full Text] [Related]
11. Significance of the preoperative intravesical instillation of doxorubicin and the oral administration of 5-fluorouracil in preventing recurrence after a transurethral resection of superficial bladder cancer. Kyushu University Urological Oncology Group.
Naito S; Iguchi A; Sagiyama K; Ariyoshi A; Osada Y; Omoto T; Kuriya N; Kumazawa J
Int J Urol; 1997 Jul; 4(4):352-7. PubMed ID: 9256323
[TBL] [Abstract][Full Text] [Related]
12. [Long-term results of intravesical prevention of recurrence with mitomycin C and adriamycin in patients with superficial bladder cancer].
Schwaibold H; Klingenberger HJ; Huland H
Urologe A; 1994 Nov; 33(6):479-83. PubMed ID: 7817443
[TBL] [Abstract][Full Text] [Related]
13. Prospective randomized phase II trial of a single early intravesical instillation of pirarubicin (THP) in the prevention of bladder recurrence after nephroureterectomy for upper urinary tract urothelial carcinoma: the THP Monotherapy Study Group Trial.
Ito A; Shintaku I; Satoh M; Ioritani N; Aizawa M; Tochigi T; Kawamura S; Aoki H; Numata I; Takeda A; Namiki S; Namima T; Ikeda Y; Kambe K; Kyan A; Ueno S; Orikasa K; Katoh S; Adachi H; Tokuyama S; Ishidoya S; Yamaguchi T; Arai Y
J Clin Oncol; 2013 Apr; 31(11):1422-7. PubMed ID: 23460707
[TBL] [Abstract][Full Text] [Related]
14. Comparison of different schedules of cytostatic intravesical instillations in patients with superficial bladder carcinoma: final evaluation of a prospective multicenter study with 419 patients.
Huland H; Klöppel G; Feddersen I; Otto U; Brachmann W; Hubmann H; Kaufmann J; Knipper W; Lantzius-Beninga F; Huland E
J Urol; 1990 Jul; 144(1):68-71; discussion 71-2. PubMed ID: 2113590
[TBL] [Abstract][Full Text] [Related]
15. Effectiveness of a single immediate mitomycin C instillation in patients with low risk superficial bladder cancer: short and long-term follow-up.
El-Ghobashy S; El-Leithy TR; Roshdy MM; El-Ganzoury HM
J Egypt Natl Canc Inst; 2007 Jun; 19(2):121-6. PubMed ID: 19034342
[TBL] [Abstract][Full Text] [Related]
16. Impact of intravesical chemotherapy on recurrence rate of recurrent superficial transitional cell carcinoma of the bladder: results of a meta-analysis.
Huncharek M; McGarry R; Kupelnick B
Anticancer Res; 2001; 21(1B):765-9. PubMed ID: 11299841
[TBL] [Abstract][Full Text] [Related]
17. Intravesical mitomycin C for superficial transitional cell carcinoma.
Bolenz C; Cao Y; Arancibia MF; Trojan L; Alken P; Michel MS
Expert Rev Anticancer Ther; 2006 Aug; 6(8):1273-82. PubMed ID: 16925493
[TBL] [Abstract][Full Text] [Related]
18. Is there an optimal treatment scheme for adjuvant intravesical therapy? Preliminary analysis of an EORTC protocol comparing early and delayed instillation with and without maintenance of either adriamycin or mitomycin-C in patients with superficial transitional carcinoma of the bladder.
Kurth KH; Bouffioux C; Sylvester R; de Pauw M
Prog Clin Biol Res; 1988; 269():525-37. PubMed ID: 3134663
[No Abstract] [Full Text] [Related]
19. [Prophylactic intravesical instillation therapy in patients with superficial bladder cancer--results of a randomized prospective study].
Tsushima T; Nasu Y; Abeki N; Noda M; Saika T; Ohmori H; Kobashi K; Ozaki Y; Matsumura Y; Tanahashi T
Nihon Hinyokika Gakkai Zasshi; 1992 Aug; 83(8):1314-21. PubMed ID: 1405170
[TBL] [Abstract][Full Text] [Related]
20. The effect of intravesical mitomycin C on the recurrence of superficial (Ta-T1) bladder cancer. A Hungarian Multicenter Study.
Kondás J; Kiss L; Határ A; Kiss A; Lukács T; Szeldeli P; Törzsök F; Bodrogi I
Int Urol Nephrol; 1999; 31(4):451-6. PubMed ID: 10668939
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
